Category: 3. Business

  • Concorde commemorative 50p coin unveiled by Royal Mint

    Concorde commemorative 50p coin unveiled by Royal Mint

    A new 50 pence coin celebrating 50 years since Concorde’s first commercial flight has been launched by the Royal Mint.

    Unveiled at the aircraft’s current home, the Aerospace Bristol Museum, the reverse or ‘tails’ side of the coin portrays the aircraft in flight, against a backdrop of a split-flap departure board, with the word Concorde appearing across the centre.

    The supersonic aircraft made its first commercial flight on 21 January 1976.

    Former chief engineer of Concorde John Britton said: “To celebrate Concorde on an official UK coin is a proud moment for everyone who dedicated their careers to keeping her in the sky.”

    Continue Reading

  • Share buyback program – 13 January 2026

    Share buyback program – 13 January 2026

    Amsterdam, 13 January 2026 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, repurchased 461,483 of its own shares in the period 5 – 9 January 2026 at an average price of €36.56. The total consideration of this repurchase was €16,873,986.

    The total number of shares repurchased under this program to date is 4,141,810 shares for a total consideration of €158,797,681 at an average price of €38.34.

    The repurchase is in accordance with the share buyback program to reduce the capital of Arcadis, as announced on 1 October 2025.

    Overviews of all transactions under this program are published in weekly press releases and on the website of Arcadis.

    Continue Reading

  • Innovation and Execution Power UCB’s Success

    Brussels, Belgium – January 13, 2026– 7:00 CET – UCB (Euronext: UCB), a global biopharmaceutical leader committed to transforming the lives of people living with severe diseases, presents at the 44th Annual J.P. Morgan Healthcare Conference its powerful growth engine, innovation-led strategy, and the expanding global impact of BIMZELX®.

    Turning Strategy into Results 

    UCB’s unwavering focus on innovation and execution excellence continues to deliver results. The company’s upgraded 2025 financial guidance underscores strong momentum and resilience, supported by a portfolio of five differentiated growth drivers —BIMZELX®, RYSTIGGO®, ZILBRYSQ®, FINTEPLA®, and EVENITY® —each addressing significant unmet medical needs through unique mechanisms of action.

    Jean-Christophe Tellier, CEO commented: “Our long-dated patent protection places us in a position of strength, underpinning resilience and enabling us to navigate uncertainty with confidence and agility. At the same time, BIMZELX® continues to expand its global footprint, having reached more than 100,000 patients worldwide —a clear validation of the recognized efficacy and differentiation of the assets. This reaffirms our intact decade-plus growth trajectory, driven by the excellence of our execution and the strength of our innovation.”

    Key Highlights from the Presentation

    • Financial Strength: Upgraded 2025 guidance (on December 5th, 2025) projects revenues exceeding €7.6 billion and an adjusted EBITDA margin above 31%, positioning UCB to deliver on its Decade+ growth strategy. 2025 financial results and the 2026 financial guidance will be announced on February 26, 2026.
    • Breakthrough Innovation: U.S. approval of KYGEVVITM, first and only approved treatment for adult and pediatric patients with Thymidine Kinase 2 deficiency, launching in Q1 2026, reinforces UCB’s commitment to addressing unmet needs. Additionally, compelling data for galvokimig in atopic dermatitis further demonstrates pipeline strength.
    • Expanded Access: 2026 BIMZELX® coverage in the U.S. has surged, adding 36 million additional patients —a +25% increase versus 2025— bringing commercial coverage above 80%, alongside broad access for Medicaid and Medicare beneficiaries.

    Confidence in Sustained Growth

    With a foundation of differentiated innovation, disciplined execution, and purpose-led performance, UCB is poised to deliver long-term value for patients, shareholders, and society.

    The CEO’s presentation and webcast from the J.P. Morgan Healthcare Conference will be available on UCB’s Investor Relations section.

    For further information, contact UCB: 

    Investor Relations
    Antje Witte 
    T +32.2.559.94.14 
    email antje.witte@ucb.com

    Sahar Yazdian
    T +32.2.559.91.37 
    email mailto:sahar.yazdian@ucb.com  

    Corporate Communications
    Laurent Schots 
    T +32.2.559.92.64 
    Email laurent.schots@ucb.com  

    About UCB 
    UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB).

    Forward looking statements 
    This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. 
    Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.
    Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.
    UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

     

    Continue Reading

  • ASX clocks best session of new year as miners charge

    ASX clocks best session of new year as miners charge

    Australia’s sharemarket has surged to nine-week highs on the back of strong commodity prices and a rebound in the heavyweight financials sector, lifting the leading indices.

    The S&P/ASX200 gained 62.6 points on Tuesday, up 0.71 per cent, to 8,822, as the broader All Ordinaries advanced 58.6 points, or 0.5 per cent, to 9,138.5.

    Only four of 11 local sectors ended the session higher, but solid gains in the materials and financials sectors launched the market to its best day of the year so far.

    The Australian dollar was buying 67.11 US cents, up from 66.98 US cents on Monday at 5pm.

    Continue Reading

  • Intra-day update: rupee registers gain against US dollar – Business Recorder

    1. Intra-day update: rupee registers gain against US dollar  Business Recorder
    2. Rupee registers gain against US dollar  Business Recorder
    3. Foreign exchange rates in Pakistan for today, January 13, 2026  Profit by Pakistan
    4. Today Open Market Currency Rates in Pakistan – Dollar, Euro, Dirham, Riyal – 12 Jan 2026  Daily Pakistan
    5. Rupee gains one paisa against dollar  Daily Times

    Continue Reading

  • PQ on Strengthening Protection for Consumers Who Purchase High Value Packages from Businesses with Knowledge of Their Insolvency

    PQ on Strengthening Protection for Consumers Who Purchase High Value Packages from Businesses with Knowledge of Their Insolvency

    Continue Reading

  • Written reply to PQ on Supporting SMEs to Adapt to Global Emphasis on Sustainability and Green Technologies

    Written reply to PQ on Supporting SMEs to Adapt to Global Emphasis on Sustainability and Green Technologies

    Continue Reading

  • Couple linked to disgraced former Wagga Wagga MP Daryl Maguire banned from managing corporations

    Couple linked to disgraced former Wagga Wagga MP Daryl Maguire banned from managing corporations

    Australia’s financial watchdog has banned a husband and wife from managing corporations for the maximum allowable period after the failure of their agribusinesses — one of which was linked to disgraced former NSW MP Daryl Maguire.

    The Australian Securities and Investment Commission (ASIC) said Jimmy Yang, also known as Jimmy Liu, and his wife Freda Feng were the directors of three agricultural companies between 2004 and 2025.

    Mr Yang was also the director of a personal services company in the same time period.

    ASIC said the pair failed to act properly and meet their obligations as company officers, including when Mr Yang offered incentives to Mr Maguire, who was the Member for Wagga Wagga between 1999 and 2018.

    Mr Maguire was forced to resign as a result of a corruption inquiry in 2018.

    The commission also found Mr Yang and Ms Feng:

    • Failed to ensure UWE Hay, United World Enterprises, Griffith and SMU Holdings complied with their statutory obligations to the Australian Taxation Office
    • Failed to maintain and keep adequate books and records for UWE Hay and United World Enterprises
    • Improperly used their position to withdraw company funds from UWE Hay’s bank accounts without explanation for the use of the funds
    • Improperly used their positions by permitting loans to be made from UWE Hay and United World Enterprises to other entities
    • Improperly used their positions to allow United World Enterprises to enter into an agreement to sponsor a work visa in exchange for United World Enterprises receiving a financial loan
    • Improperly used their positions to sell a vehicle owned by United World Enterprises and use the proceeds to purchase a new vehicle for UWE Hay, and
    • Failed to prevent UWE Hay and United World Enterprises from insolvent trading.

    ASIC said at the time of its decision, the companies owed a combined total of nearly $57 million, including almost $111,000 to the ATO, $6,500 for employee entitlements, as well as “significant debts to small businesses in the agriculture industry”.

    Mr Yang and Ms Feng are both disqualified from managing corporations until December 17, 2030, and have the right to seek a review of the decision through the Administrative Review Tribunal.

    Continue Reading

  • New Energy Expert Insights: Automation of solar installation and maintenance with Alan Fenelon, Chief Executive Officer of Solar Energy Robotics

    New Energy Expert Insights: Automation of solar installation and maintenance with Alan Fenelon, Chief Executive Officer of Solar Energy Robotics

    In this edition of New Energy Expert Insights, we sat down with Alan Fenelon, Chief Executive Officer of Solar Energy Robotics, to discuss the automation of solar installation and maintenance.

    Solar Energy Robotics

    Solar Energy Robotics (SER) is an Australian company delivering advanced robotic solutions for the solar energy sector. SER designs and manufactures specialist robotic systems in-house where unique local needs demand innovation. SER is also the Australian partner for Sunpure Technology, a partnership focused on introducing and supporting utility scale install and cleaning solutions to Australia.

    This dual capability makes SER unique in Australia – able to innovate locally, leverage global best-in-class systems, and deliver end-to-end robotic solutions that give utility-scale solar projects a decisive competitive edge.

    Alan Fenelon is the Chief Executive Officer at SER. He brings more than twenty-five years of experience in mining technology and renewable energy.

    What are you seeing in the Australian solar robotic market?

    Australia’s solar robotic market is nascent. There are no existing solar farms in Australia that currently use robotic cleaning. In part, this is due to an underappreciation of the impact of soiling on projects. Unlike their international counterparts, most Australian developers do not collect data on soiling. As a result, Australian developers do not fully understand the impact of soiling on operational efficiency and so do not consider incorporating robotic technology into the project during the planning phase. More simply put, nobody requests autonomous cleaners to be ‘designed in’, therefore they never are. And a retrofit is always a compromise.

    • I think the big variable in there is that no one is really looking at soiling data”

    SER endeavours to target this persistent gap in Australia’s market by introducing a localised and fit for purpose robotic solution. The technology itself is highly mature and reliable, and robotic solar cleaning solutions have been available globally for nearly a decade. From a hardware and software standpoint, these systems are scalable, cost effective and field proven. The real issue with maturity lies within the Australian market. The barrier isn’t technological; the barrier lies in the lack of consideration given to integrating automation during the design and development phases of solar projects.

    SER is actively working to shift this mindset, advocating for cleaning systems to be considered in the project planning phase.

    What role do you see solar energy robotics playing in shaping Australia’s solar robotic market?

    SER has two strands of business. On the one hand it develops and manufactures solutions end to end that target specific operational gaps in the local market where competition is scarce. On the other hand, SER partners with market leaders Sunpure Technology for the volume-based utility scale solar energy market.

    All SER’s range of autonomous cleaners offered are waterless and self-sufficient. They are designed to be permanently installed on site in most cases. In its own product suite, SER adopts the concept of a literal and metaphorical ‘chassis’, one that is configured to various use cases without having to redesign anything from scratch. It makes for more effective client support too.

    Due to its relationship with Sunpure Technology, SER is now placed to also offer module installation robots as a wet rental and or outright purchase. Automation of this task  has the ability to reduce over half of the investment and duration associated with module installs. It’s also more accurate and much safer because there is almost zero manual handling.

    Why would a developer use a robot over a human?

    Robots provide logistical and financial benefits to developers.

    From an operations and maintenance (O&M) and Life of Farm perspective, robotic cleaners boost performance and daily yield by ensuring soiling does not occur on solar panels. Soiling is the accumulation of particles and debris on the surface of solar panels, which reduces the energy production of the panels. By installing robotics into a project (a one-off installation), the developer avoids the ongoing complexities of traditional labour (for example, workplace health and safety risks and training requirements). Further, as robotics technology can be designed into a project during the planning phase, developers have a unique opportunity to better design solar farms to maximise operational efficiency in ways not possible with human labour forces.

    Financially, robotic cleaning significantly reduces labour dependency and capital costs, providing developers with an accurate, upfront investment that leads to long-term savings across the entire operation and maintenance of a project. For example, individual robots can clean semi uninterrupted solar rows up to 2 kilometres, offering a level of efficiency unmatched by traditional labour.

    How do you anticipate the role of human workers changing as automation becomes more prevalent in the solar industry?

    Although automation will impact certain workforces, it will also encourage skills to be reallocated across the new energy industry. In the specific case of solar cleaning and installation, there is already a shortage of labour, and so the impact is fairly localised. However, when automation moves beyond solar cleaning into broader operations and maintenance activities (where there is a larger workforce), the impact will be more noticeable. The answer may be to transition that workforce into new roles focused on managing, maintaining, and optimising robotic systems.

    Are there any technical limitations or challenges that automated systems face in solar maintenance, and how are these being addressed?

    The biggest limitation for robotic cleaning solutions is deployment onto already designed and operating solar farms. Retrofitting automation into existing layouts, especially when those layouts have not been designed with robotics in mind, is technically nuanced, costly and compromise heavy.

    In design stages, there are virtually no limitations on implementation. It simply requires intentional design choices to accommodate robotic technology. A sympathetic design sees longer, less interrupted arrays. Footprint permitting, it might be as simple as relocating inverters and some services to achieve this. When ‘designed in’ the cost tends to be less than 1% of the capital cost of the project overall. The client has a zero impact, technology solution for the least investment.

    They achieve Every Panel Every Day (EPED) cleaning with zero associated effort and thus derisk the Life of Farm in soiling terms; achieving a highly predictable 0.5% soiling loss versus the anomalous and much higher losses when it’s left to nature and some intermittent cleaning.

    In reflecting the 0.5%, highly predictable and de-risked soiling losses, the even more obvious upside is that the optimised farm does not have to be as large. Think of the ~20% reduction of savings achieved if you could deliver the same, consistent energy from a smaller footprint. Less trackers, less panels, fewer inverters, shorter projects with fewer people and less real estate.

    The future

    What are the most promising technological advancements in the automation of solar panel maintenance?

    The most promising technological advancements are developing a robotic system that can, while carrying out cleaning, monitor the condition of the installed solar panels. There is a clear synergy in condition monitoring while solar panels are being cleaned and maintained. The next step in the industry is to combine the benefits of solar cleaning with continuous, ongoing solar monitoring.

    What excites you most about the future of solar and automation?

    The most exciting part about the future of solar and automation is the huge potential for innovation. The benefit of having no active installations in Australia is that every installation is a step into the future. The sheer number of potential installations leaves an enticing space for the deployment of new robotics technology.

    Other than that, the future hopefully holds increased installations of solar robotic cleaners, which ultimately boosts Australia into a cleaner, more sustainable and more efficient future.

    Continue Reading

  • Gold Steadies After Surging on Worries Over Fed Independence – Bloomberg.com

    1. Gold Steadies After Surging on Worries Over Fed Independence  Bloomberg.com
    2. Gold cracks $4,600/oz as Fed uncertainty fans safe-haven rush  Reuters
    3. Gold prices hit record high above $4,600/oz on Iran unrest, Fed indictment threat  Investing.com
    4. Power price rallies push gold, silver to record highs on safe-haven demand  KITCO
    5. Gold, silver hit record highs as US Justice Dept probe targets Federal Reserve  Geo News

    Continue Reading